The Journal of the Korean dental association (대한치과의사협회지)

The Korean Dental Association (대한치과의사협회)
권호 표지

Biochemical bone markers of bisphosphonate-related osteonecrosis of the jaw (BRONJ) and nonbisphosphonate drugs in osteonecrosis of the jaw

임상가를 위한 특집 2 - Bisphosphonate-related osteonecrosis of the jaw(BRONJ)에 대한 biochemical bone markers와 악골괴사와 연관된 nonbisphosphonate drugs

  • Lee, Deok-Won (Department of Oral and Maxillofacial Surgery, Center for Refractory Jawbone Diseases, School of Dentistry, Kyung Hee University) ;
  • Lee, Hyun-Woo (Department of Oral and Maxillofacial Surgery, Center for Refractory Jawbone Diseases, School of Dentistry, Kyung Hee University) ;
  • Kwon, Yong-Dae (Department of Oral and Maxillofacial Surgery, Center for Refractory Jawbone Diseases, School of Dentistry, Kyung Hee University)
  • 이덕원 (경희대학교 치의학전문대학원 구강악안면외과학교실, 난치성턱뼈질환센터) ;
  • 이현우 (경희대학교 치의학전문대학원 구강악안면외과학교실, 난치성턱뼈질환센터) ;
  • 권용대 (경희대학교 치의학전문대학원 구강악안면외과학교실, 난치성턱뼈질환센터)
  • Received : 2014.03.13
  • Accepted : 2014.03.26
  • Published : 2014.04.01
Download PDF
⟨ Previous Next ⟩

Abstract

Bisphosphonates are widely used in the treatment of many medical conditions, such as osteoporosis, multiple myeloma, Paget's disease, etc. However, side effect has been documented in the published data during the past years, osteonecrosis of the jaw in patients receiving long-term bisphosphonate therapy. Although pathogenesis of BRONJ(bisphophonate-related osteonecrosis of the jaw) is not yet fully understood, it is currently known to be a disease associated with suppressed bone turnover by bisphopbonate. Recent literature has indicated a similar association with nonbisphosphonate drugs used in cancer therapy including monoclonal antibodies denosumab and bevacizumab and multikinase inhibitor sunitinib. Accordingly, many studies have been carried out on the biochemical markers examination to assess the risk for BRONJ. The treatment of BRONI is reported with a review of the relevant literature. However, there is still a controversial discussion about the adequate treatment. It is necessary to accumulate further studies in order to establish more useful biochemical markers and effective treatment for BRONJ.

Keywords

References

  1. Saad, F. and A. Lipton, Clinical benefits and considerations of bisphosphonate treatment in metastatic bone disease. Semin Oncol, 2007. 34(6 Suppl 4): p. S17-23.
  2. Marx, R.E., Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg, 2003. 61(9): p. 1115-7. https://doi.org/10.1016/S0278-2391(03)00720-1
  3. Lazarovici, T.S., et al., Serologic bone markers for predicting development of osteonecrosis of the jaw in patients receiving bisphosphonates. J Oral Maxillofac Surg, 2010. 68(9): p. 2241-7. https://doi.org/10.1016/j.joms.2010.05.043
  4. Khosla, S., et al., Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res, 2007. 22(10): p. 1479-91. https://doi.org/10.1359/jbmr.0707onj
  5. Ruggiero, S.L., et al., American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw - 2009 update. Aust Endod J, 2009. 35(3): p. 119-30. https://doi.org/10.1111/j.1747-4477.2009.00213.x
  6. Williamson, R.A., Surgical management of bisphosphonate induced osteonecrosis of the jaws. Int J Oral Maxillofac Surg, 2010. 39(3): p. 251-5. https://doi.org/10.1016/j.ijom.2009.11.014
  7. Carlson, E.R. and J.D. Basile, The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg, 2009. 67(5 Suppl): p. 85-95.
  8. Vasikaran, S., et al., Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int, 2011. 22(2): p. 391-420. https://doi.org/10.1007/s00198-010-1501-1
  9. Rosen, H.N., et al., Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int, 2000. 66(2): p. 100-3. https://doi.org/10.1007/PL00005830
  10. Marx, R.E., J.E. Cillo, Jr., and J.J. Ulloa, Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg, 2007. 65(12): p. 2397-410. https://doi.org/10.1016/j.joms.2007.08.003
  11. Schwartz, H.C., Serum CTX testing. J Oral Maxillofac Surg, 2008. 66(6): p. 1319-20; author reply 1320.
  12. Kwon, Y.D., et al., Correlation between serum C-terminal cross-linking telopeptide of type I collagen and staging of oral bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg, 2009. 67(12): p. 2644-8. https://doi.org/10.1016/j.joms.2009.04.067
  13. Bagan, J.V., et al., Collagen telopeptide (serum CTX) and its relationship with the size and number of lesions in osteonecrosis of the jaws in cancer patients on intravenous bisphosphonates. Oral Oncol, 2008. 44(11): p. 1088-9. https://doi.org/10.1016/j.oraloncology.2008.01.012
  14. Kunchur, R., et al., Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws. J Oral Maxillofac Surg, 2009. 67(6): p. 1167-73. https://doi.org/10.1016/j.joms.2009.02.004
  15. Ardine, M., et al., Could the long-term persistence of low serum calcium levels and high serum parathyroid hormone levels during bisphosphonate treatment predispose metastatic breast cancer patients to undergo osteonecrosis of the jaw? Ann Oncol, 2006. 17(8): p. 1336-7. https://doi.org/10.1093/annonc/mdl045
  16. Lehrer, S., et al., Normal serum bone markers in bisphosphonate-induced osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2008. 106(3): p. 389-91. https://doi.org/10.1016/j.tripleo.2008.01.033
  17. Kim, J.W., et al., Prospective biomarker evaluation in patients with osteonecrosis of the jaw who received bisphosphonates. Bone, 2013. 57(1): p. 201-5. https://doi.org/10.1016/j.bone.2013.08.005
  18. Martinez, J., et al., Bone turnover markers in Spanish postmenopausal women: the Camargo cohort study. Clin Chim Acta, 2009. 409(1-2): p. 70-4. https://doi.org/10.1016/j.cca.2009.08.020
  19. Trento, L.K., et al., Role of type I collagen C telopeptide, bone-specific alkaline phosphatase and osteocalcin in the assessment of bone status in postmenopausal women. J Obstet Gynaecol Res, 2009. 35(1): p. 152-9. https://doi.org/10.1111/j.1447-0756.2008.00868.x
  20. Lee, J.J., et al., Factors predicting the prognosis of oral alendronate-related osteonecrosis of the jaws: a 4-year cohort study. Head Neck, 2013. 35(12): p. 1787-95. https://doi.org/10.1002/hed.23235
  21. Bowers, G.N., Jr. and R.B. McComb, Measurement of total alkaline phosphatase activity in human serum. Clin Chem, 1975. 21(13): p. 1988-95.
  22. Raisz, L., et al., Short-term risedronate treatment in postmenopausal women: effects on biochemical markers of bone turnover. Osteoporos Int, 2000. 11(7): p. 615-20. https://doi.org/10.1007/s001980070083
  23. Looker, A.C., et al., Clinical use of biochemical markers of bone remodeling: current status and future directions. Osteoporos Int, 2000. 11(6): p. 467-80. https://doi.org/10.1007/s001980070088
  24. Baim, S. and P.D. Miller, Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw. J Bone Miner Res, 2009. 24(4): p. 561-74. https://doi.org/10.1359/jbmr.090203
  25. Lehrer, S., et al., Bisphosphonate-induced osteonecrosis of the jaws, bone markers, and a hypothesized candidate gene. J Oral Maxillofac Surg, 2009. 67(1): p. 159-61. https://doi.org/10.1016/j.joms.2008.09.015
  26. Kwon, Y.D., et al., Retrospective study of two biochemical markers for the risk assessment of oral bisphosphonate-related osteonecrosis of the jaws: can they be utilized as risk markers? Clin Oral Implants Res, 2011. 22(1): p. 100-5. https://doi.org/10.1111/j.1600-0501.2010.01965.x
  27. in Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride. 1997: Washington (DC).
  28. Holick, M.F., Vitamin D deficiency. N Engl J Med, 2007. 357(3): p. 266-81. https://doi.org/10.1056/NEJMra070553
  29. Hwang, Y.C., et al., Optimal serum concentration of 25-hydroxyvitamin D for bone health in older Korean adults. Calcif Tissue Int, 2013. 92(1): p. 68-74. https://doi.org/10.1007/s00223-012-9669-3
  30. MacLaughlin, J. and M.F. Holick, Aging decreases the capacity of human skin to produce vitamin D3. J Clin Invest, 1985. 76(4): p. 1536-8. https://doi.org/10.1172/JCI112134
  31. Hokugo, A., et al., Increased prevalence of bisphosphonate-related osteonecrosis of the jaw with vitamin D deficiency in rats. J Bone Miner Res, 2010. 25(6): p. 1337-49. https://doi.org/10.1002/jbmr.23
  32. Kim, S.W., et al., Early changes in biochemical markers of bone turnover predict bone mineral density response to antiresorptive therapy in Korean postmenopausal women with osteoporosis. Endocr J, 2005. 52(6): p. 667-74. https://doi.org/10.1507/endocrj.52.667
  33. Pazianas, M., Osteonecrosis of the jaw and the role of macrophages. J Natl Cancer Inst, 2011. 103(3): p. 232-40. https://doi.org/10.1093/jnci/djq516
  34. Baron, R., S. Ferrari, and R.G. Russell, Denosumab and bisphosphonates: different mechanisms of action and effects. Bone, 2011. 48(4): p. 677-92. https://doi.org/10.1016/j.bone.2010.11.020
  35. Troeltzsch, M., et al., Physiology and pharmacology of nonbisphosphonate drugs implicated in osteonecrosis of the jaw. J Can Dent Assoc, 2012. 78: p. c85.
  36. Bekker, P.J., et al., A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res, 2004. 19(7): p. 1059-66. https://doi.org/10.1359/JBMR.040305
  37. Lumachi, F., et al., Cancer-induced hypercalcemia. Anticancer Res, 2009. 29(5): p. 1551-5.
  38. Sivolella, S., et al., Denosumab and anti-angiogenetic drug-related osteonecrosis of the jaw: an uncommon but potentially severe disease. Anticancer Res, 2013. 33(5): p. 1793-7.
  39. Guarneri, V., et al., Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat, 2010. 122(1): p. 181-8. https://doi.org/10.1007/s10549-010-0866-3
  40. Lazarovici, T.S., et al., Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients. J Oral Maxillofac Surg, 2009. 67(4): p. 850-5. https://doi.org/10.1016/j.joms.2008.11.015
  41. Hoff, A.O., et al., Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res, 2008. 23(6): p. 826-36. https://doi.org/10.1359/jbmr.080205
  42. Harper, K.D., et al., Osteosarcoma and teriparatide? J Bone Miner Res, 2007. 22(2): p. 334.
  43. Kwon, Y.D., et al., Short-term teriparatide therapy as an adjunctive modality for bisphosphonate-related osteonecrosis of the jaws. Osteoporos Int, 2012. 23(11): p. 2721-5. https://doi.org/10.1007/s00198-011-1882-9
  44. Narvaez, J., et al., Lack of response to teriparatide therapy for bisphosphonate-associated osteonecrosis of the jaw. Osteoporos Int, 2013. 24(2): p. 731-3. https://doi.org/10.1007/s00198-012-1918-9
  45. Adornato, M.C., I. Morcos, and J. Rozanski, The treatment of bisphosphonate-associated osteonecrosis of the jaws with bone resection and autologous platelet-derived growth factors. J Am Dent Assoc, 2007. 138(7): p. 971-7. https://doi.org/10.14219/jada.archive.2007.0294
  46. Freiberger, J.J., Utility of hyperbaric oxygen in treatment of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg, 2009. 67(5 Suppl): p. 96-106.
  47. Curtis, J.R., et al., Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday. Osteoporos Int, 2008. 19(11): p. 1613-20. https://doi.org/10.1007/s00198-008-0604-4
  48. Kwon, Y.D., et al., Oral bisphosphonate-related osteonecrosis of the jaws: favorable outcome after bisphosphonate holiday. Quintessence Int, 2009. 40(4): p. 277-8.
  49. Thumbigere-Math, V., et al., Bisphosphonate-related osteonecrosis of the jaw: clinical features, risk factors, management, and treatment outcomes of 26 patients. J Oral Maxillofac Surg, 2009. 67(9): p. 1904-13. https://doi.org/10.1016/j.joms.2009.04.051